← boardnext 2027-01-15next 2028-09
XBIT
XBiotech, Inc.distress 1/10 · well-funded / low risk$2.270%today-35% from 52w high
Lead: Axial Spondyloarthritis
Revenue
pre-revenue
Liquidity
$115M
Runway
2.7 yrs
Shares 1y
0%
Price & events
-14.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-0.9%
1W
-2.6%
1M
-10.3%
3M
-15.3%
6M
-26.8%
1Y
-64.4%
2Y
-85.8%
5Y
-83.7%
All
Overview
- Market Cap
- $69.21M
- Volume
- 8.32K
- 52 Week Range
- $2.12 – $3.50
- Total Shares
- 30.49M
- Float Shares
- 22.84M
- Short %
- 1.06%
- % Held by Insiders
- 24.33%
- % Held by Institutions
- 6.81%
- RVOL
- 0.21x
- Beta
- 0.84
Pipeline stages · 2 programs
Natrunix 400 mg, Methotrexate (MTX)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
vilamakitug
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-01-15 Estimated 50% readout ~2027-03-01 | Phase 2 | Natrunix 400 mg, Methotrexate (MTX) | Rheumatoid Arthritis | — | not yet recruiting |
| 2028-09 Estimated 50% readout ~2028-10-16 | Phase 2 | vilamakitug | Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpA, Nr-axSpA | — | not yet recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 30,487,731 · 0 offerings/1y · 0 PIPEs
- 2025-10-038-Kmaterial_agreement
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Axial Spondyloarthritis
Recent news
- 2026-07-09XBiotech Inc. (XBIT) Slides 2.97% as Shares Approach Key Support at $2.18 - MFI Overbought - dars.gov.et
- 2026-07-08XBiotech focuses on antibody pipeline as biotech sector evolves - Ad-hoc-news.de
- 2026-06-28XBiotech Inc. (XBIT) Holds Steady at $2.33 as Key Support and Resistance Levels Converge - Volume Dry Up - dars.gov.et
- 2026-06-21XBiotech (XBIT) Dips 2.53% as Shares Test Support Near $2.19 - Catalyst Driven Stocks - dars.gov.et
- 2026-06-20XBiotech Inc. (XBIT) Nears Key Support After 2.5% Decline - Advance Decline Volume - dars.gov.et
- 2026-06-15XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.